Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 2,600 shares of the stock on the open market in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $6.66, for a total transaction of $17,316.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Regulus Therapeutics (NASDAQ:RGLS) traded up 1.34% during mid-day trading on Friday, hitting $6.81. The stock had a trading volume of 43,818 shares. Regulus Therapeutics has a one year low of $5.40 and a one year high of $11.88. The stock’s 50-day moving average is $7. and its 200-day moving average is $7.98. The company’s market cap is $295.3 million.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.10. On average, analysts predict that Regulus Therapeutics will post $-0.89 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on RGLS shares. Analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $16.20.

Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.

Receive News & Ratings for Regulus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.